This inventor holds 3 USPTO granted patents. Top assignees: Smithkline Beecham Corporation, Glaxosmithkline LLC. Active years: 2006-2010.
Company Filing History:
Years Active: 2006-2010
Title: The Innovative Contributions of Steven Ludbrook
Introduction
Steven Ludbrook is a notable inventor based in Stevenage, GB. He has made significant contributions to the field of biomedical research, particularly in the study of osteopontin and its interactions with integrins. With a total of 3 patents to his name, Ludbrook's work has implications for therapeutic approaches to inflammatory diseases.
Latest Patents
Ludbrook's latest patents focus on methods of screening for inhibitors of osteopontin. Specifically, he has identified that amino acids 136 to 142 and amino acids 162 to 168 of human osteopontin constitute two critical sites at which osteopontin interacts with α4 integrins. Products capable of disrupting these interactions are deemed useful in therapy, particularly for treating inflammatory diseases.
Career Highlights
Throughout his career, Ludbrook has worked with prominent companies in the pharmaceutical industry, including SmithKline Beecham Corporation and GlaxoSmithKline LLC. His experience in these organizations has allowed him to develop and refine his innovative ideas, contributing to advancements in medical research.
Collaborations
Ludbrook has collaborated with several professionals in his field, including Simon Thomas Barry and Carmel Horgan. These collaborations have further enriched his research and development efforts.
Conclusion
Steven Ludbrook's innovative work in the field of osteopontin research highlights his contributions to medical science. His patents and collaborations reflect a commitment to advancing therapeutic options for inflammatory diseases.